Berberine hydrochloride-loaded liposomes-in-hydrogel microneedles achieve the efficient treatment for psoriasis
Materials Today Bio · 2025-06 · 32 · 101795
DOI: 10.1016/j.mtbio.2025.101795 ↗Kurz gefasst
Fachartikel in der Zeitschrift Materials Today Bio, 2025-06. Verfasst von Si Shen und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Anhui University of Chinese Medicine, No. 350, Long Zi Hu Road, Hefei, 230012, China. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Anhui Provincial Quality Engineering Project, Natural Science Foundation of Anhui Province, Anhui Provincial Department of Education.
Abstract (Originalsprache)
Psoriasis is a common immune-mediated squamous skin disease, primarily characterized by the over proliferation of keratinocytes and a significant thickening of the stratum corneum. Traditional systemic drug delivery therapies often fall short due to low drug bioavailability and significant toxic side effects. Topical medications, while capable of achieving local or systemic treatment via transdermal routes, face limitations in psoriasis patients due to the abnormal thickening of the epidermis, which reduces skin permeability and hampers drug penetration efficiency. Hydrogel microneedles, as an emerging transdermal drug delivery technology, offer significant advantages such as high permeability, ease of use, low toxicity and side effects, and controlled release. Therefore, this study developed a liposome-hydrogel microneedle delivery system for the administration of berberine hydrochloride. We successfully prepared berberine hydrochloride-loaded liposomes (Ber-LPs) with high encapsulation efficiency and good stability, and integrated them into hydrogel microneedles crosslinked with PVA and PEGDA (Ber-LPs-PEGDA&PVA MNs) through a photocuring method. These microneedles exhibit an intact structure, high mechanical strength, and effective skin penetration. In vivo studies on anti-psoriatic effects showed that, compared to the model group, Ber-LPs-PEGDA&PVA MNs significantly alleviated imiquimod-induced psoriasis-like symptoms in mice, reduced skin epidermal thickness, decreased the expression levels of inflammatory cytokines, and lowered the expression of CD31 and VEGF, demonstrating excellent therapeutic efficacy. Additionally, the microneedles exhibited good drug release properties, antioxidant capacity, and biocompatibility. The novel hydrogel microneedle drug delivery system developed in this study offers a safe and effective solution for the treatment of psoriasis, with significant potential for clinical application.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy, Anhui University of Chinese Medicine, No. 350, Long Zi Hu Road, Hefei, 230012, China.
Förderung
- Anhui Provincial Quality Engineering Project
- Natural Science Foundation of Anhui Province
- Anhui Provincial Department of Education
- Anhui University of Chinese Medicine
Zitieren
APA
Shen, S., Shen, W., Wang, L., Sun, B., Zhang, Y., Zhang, Y., Jia, R., Wu, Y., Chen, X., Cao, K., Fang, Y., & Xia, H. (2025). Berberine hydrochloride-loaded liposomes-in-hydrogel microneedles achieve the efficient treatment for psoriasis. Materials Today Bio, 32, 101795. https://doi.org/10.1016/j.mtbio.2025.101795
Vancouver
Shen S, Shen W, Wang L, Sun B, Zhang Y, Zhang Y, et al. Berberine hydrochloride-loaded liposomes-in-hydrogel microneedles achieve the efficient treatment for psoriasis. Materials Today Bio. 2025;32:101795. doi:10.1016/j.mtbio.2025.101795
BibTeX
@article{Shen2025,
author = {Shen, Si and Shen, Wang and Wang, Lu and Sun, Bin and Zhang, Yongli and Zhang, Yong and Jia, Ruoyang and Wu, Yang and Chen, Xue and Cao, Keang and Fang, Yuqing and Xia, Hongmei},
title = {Berberine hydrochloride-loaded liposomes-in-hydrogel microneedles achieve the efficient treatment for psoriasis},
journal = {Materials Today Bio},
year = {2025},
volume = {32},
pages = {101795},
doi = {10.1016/j.mtbio.2025.101795}
}
EUVIMED